Effects of nonprescription therapies on vestibular migraine: a questionnaire‐based observational study

Abstract

AbstractBackgroundVestibular migraine (VM) is a common cause of recurrent vertigo. Migraine headache preventative therapies are currently prescribed to control vertigo symptoms in VM. Clinical trials of nutraceuticals for migraine headache prevention have shown positive outcomes, but, to date, there have been no studies to assess their effectiveness in the management of VM.AimsTo report the effects of nonprescription therapy management on VM symptoms.MethodsWe undertook a prospective, questionnaire‐based assessment of patients diagnosed with VM between November 2019 and August 2021 at two Sydney tertiary referral clinics. Patients were advised on optimising sleep, hydration, exercise and nutrition and instructed to use an over‐the‐counter combination product containing riboflavin 200 mg, magnesium 150 mg, coenzyme Q10 75 mg and feverfew 200 mcg. Symptom severity and frequency were assessed using the Dizziness Handicap Inventory (DHI), the Vertigo Symptom Score short‐form (VSS‐sf) and two visual analogue scales for severity (VAS‐s) and frequency (VAS‐f) before and 3 months after commencing treatment.ResultIn 82 participants (78% female; mean age, 44 ± 14 years) we recorded a decrease in DHI (mean, 16.8 [95% confidence interval (CI), 12.8–20.9], VSS‐sf (9.3, 7.1–11.5), VAS‐s (3.0, 2.2–3.8) and VAS‐f (2.8, 2.1–3.4), equating to an improvement of 44.1%, 44.9%, 44.1% and 38.9% for each measure respectively. On the DHI and VSS‐sf, 41 (50%) and 44 (53.7%) patients showed improvement in their symptoms; 39 (47.6%) and 36 (43.9%) patients noted no change and two patients reported worsening. The supplement was well‐tolerated.ConclusionsThe results provide preliminary evidence that VM symptom frequency and severity can be reduced by using nonprescription therapies.